Key facts
- Diagens Biotechnology (HKG: 02526)’s last known valuation is $1.3B (Mar 2026).
- It has raised $214.9M; the latest was IPO ($114.9M) in Mar 2026.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Diagens Biotechnology (HKG: 02526)
- ·The full record, as it builds
Funding rounds
No funding rounds for Diagens Biotechnology (HKG: 02526) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diagens Biotechnology (HKG: 02526)
Hangzhou Diagens Biotechnology Co Ltd is a medical devices company focusing on developing medical imaging products and services. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping which the company intends to sell in China and globally as a customized computer pre-installed with the software.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2016
- Employees
- 182
- Website
- diagens.com/
- Ownership
- Publicly Held
Diagens Biotechnology (HKG: 02526) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diagens Biotechnology (HKG: 02526) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diagens Biotechnology (HKG: 02526) in its N-PORT filings yet. We sweep new filings monthly.